Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years

Jolly, Elaine; Bjarnason, Nina H.; Neven, Patrick; Plouffe, Leo; Johnston, C. Conrad; Watts, Steven; Arnaud, Claude D.; Mason, Timothy M.; Crans, Gerald; Akers, Robin; Draper, Michael W.

doi:10.1097/01.gme.0000058772.59606.2a

Cited by 107 publications

(56 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the MORE study which was the largest clinical trial on raloxifene, 7705 postmenopausal women with osteoporosis were treated with raloxifene at a dosage of 60-120 mg/day or with a placebo for 3 years, showed that after 1 year, raloxifene 60 mg/day decreased the risk for new clinical vertebral fractures for 68% compared with placebo in the overall study population and by 60% in women with prevalent vertebral fractures, who are at greater risk for subsequent fractures. Several other studies have demonstrated similar effects of raloxifene on bone loss (12). Raloxifene induces a decreases in biochemical markers of bone turnover that correlate with a subsequent increase in bone mineral density (BMD).…”

Section: Resultsmentioning

confidence: 86%

Correlation of bone mineral density with biochemical markers in post menopausal women

Agrawal

Jain

Mahajan

et al. 2009

Indian J Clin Biochem

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 86%

Correlation of bone mineral density with biochemical markers in post menopausal women

Agrawal

Jain

Mahajan

et al. 2009

Indian J Clin Biochem

View full text Add to dashboard Cite

show abstract

“…well documented that treating postmenopausal women or monkeys with HRT increases bone mineral density (27,29,40,41,49,62). However, an increase in bone mineral density is not usually detected until after 1 yr of HRT, and studies examining change in bone mineral density after 6 mo of HRT do not detect an effect (29,62).…”

Section: E764 Estrogen Decreases Body Weight In Monkeysmentioning

confidence: 99%

Selective estrogen receptor modulator promotes weight loss in ovariectomized female rhesus monkeys (Macaca mulatta) by decreasing food intake and increasing activity

Sullivan

Shearin

Koegler

et al. 2012

American Journal of Physiology-Endocrinology and Metabolism

View full text Add to dashboard Cite

Sullivan EL, Shearin J, Koegler FH, Cameron JL. Selective estrogen receptor modulator promotes weight loss in ovariectomized female rhesus monkeys (Macaca mulatta) by decreasing food intake and increasing activity. Am J Physiol Endocrinol Metab 302: E759 -E767, 2012. First published January 17, 2012; doi:10.1152/ajpendo.00327.2011.-The effect of hormone replacement therapy (HRT) on body weight in postmenopausal women is controversial, with studies reporting an increase, a decrease, and no change in body weight. To examine estrogen receptor actions on body weight, we investigated the effects of treatment with a selective estrogen receptor modulator (SERM) on body weight, food intake, and activity and metabolic rate in a nonhuman primate model. Eighteen ovariectomized female rhesus monkeys were treated with a nonsteroidal SERM (GSK232802A, 5 mg/kg po) for 3 mo. GSK232802A decreased lutenizing hormone (P Ͻ 0.0001) and follicle-stimulating hormone levels (P Ͻ 0.0001), consistent with the estrogenic action of the compound. GSK232802A treatment produced a small but sustained weight loss (4.6 Ϯ 1.0%, P Ͻ 0.0001) and reduced adiposity (P Ͻ 0.0001), which was due at least in part to a suppression of food intake (3.6 Ϯ 3.7%, P Ͻ 0.0001). Physical activity increased during the 3rd mo of treatment (P ϭ 0.04). Baseline activity level and the change in activity due to treatment were correlated, with the most sedentary individuals exhibiting increased physical activity during the 1st mo of treatment (P ϭ 0.02). Metabolic rate did not change (P ϭ 0.58). These results indicate that GSK232802A treatment reduces body weight and adiposity in ovariectomized nonhuman primates by suppressing food intake and increasing activity, particularly in the most sedentary individuals. These findings suggest that SERM treatment may counteract weight gain in postmenopausal women.hormone replacement therapy; obesity; menopause; body fat WOMEN GAIN WEIGHT IN ADULTHOOD during the menopausal transition (16,31,45,50,53,56). However, it is unclear whether weight gain is due to age-related changes in metabolism and lifestyle, such as eating more or exercising less, or due to the decrease in ovarian hormones that occurs with menopause. The effects of hormone replacement therapy (HRT) on the body weights of postmenopausal women are controversial. Many women believe that HRT increases body weight, and 18% of hormone replacement users report weight gain as the main reason for discontinuing HRT (63,78). However, the idea that HRT increases body weight is supported by only a few studies (5, 36). The majority of studies report either that postmenopausal women on HRT have lower body weight than nonusers (82, 83) or that HRT decreases (28, 29, 47) or does not affect postmenopausal weight gain (10,84,86,91), and a few studies report that HRT causes weight loss (20). The controversy around the effects of HRT on body weight in postmenopausal women may be related in part to differing effects of the various HRT regimens that are in common use, including differences i...

show abstract

“…88 In the prevention trials, it was reported that fewer women in the raloxifene treatment group progressed from normal to osteopenia, and from osteopenia to osteoporosis. 89 In addition to its skeletal effects, the MORE trial demonstrates that raloxifene reduces breast cancer by 76% in postmenopausal women with osteoporosis. 90 The recent results of Continuing Outcomes of Raloxifene Evaluation (CORE), the extension arm of the MORE trial, confirm that the breast cancer reduction effect in osteoporotic women lasts up to 8 years, with a reduction rate of 66%.…”

Section: Newer Agents Combination Therapy Selective Estrogen Receptomentioning

confidence: 99%

Canadian Consensus Conference on Osteoporosis, 2006 Update

Brown¹,

Fortier²,

Frame

et al. 2006

Journal of Obstetrics and Gynaecology Canada

View full text Add to dashboard Cite

Objective-To provide guidelines for the health care provider on the diagnosis and clinical management of postmenopausal osteoporosis.Outcomes-Strategies for identifying and evaluating high-risk individuals, the use of bone mineral density (BMD) and bone turnover markers in assessing diagnosis and response to management, and recommendations regarding nutrition, physical activity, and the selection of pharmacologic therapy to prevent and manage osteoporosis. Values-The quality of evidence is rated using the criteria described in the report of the Canadian Task Force on the Periodic Health Examination. Recommendations for practice are ranked according to the method described in this report.

show abstract

Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years

Cited by 107 publications

References 33 publications

Correlation of bone mineral density with biochemical markers in post menopausal women

Correlation of bone mineral density with biochemical markers in post menopausal women

Selective estrogen receptor modulator promotes weight loss in ovariectomized female rhesus monkeys (Macaca mulatta) by decreasing food intake and increasing activity

Canadian Consensus Conference on Osteoporosis, 2006 Update

Contact Info

Product

Resources

About